Open‐label, proof‐of‐concept study of brexanolone in the treatment of severe postpartum depression

OBJECTIVE: Preclinical evidence indicates that rapid changes in levels of allopregnanolone, the predominant metabolite of progesterone, confer dramatic behavioral changes and may trigger postpartum depression (PPD) in some women. Considering the pathophysiology of PPD (i.e., triggered by reproductiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanes, Stephen J., Colquhoun, Helen, Doherty, James, Raines, Shane, Hoffmann, Ethan, Rubinow, David R., Meltzer‐Brody, Samantha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396368/
https://www.ncbi.nlm.nih.gov/pubmed/28370307
http://dx.doi.org/10.1002/hup.2576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396368/
https://www.ncbi.nlm.nih.gov/pubmed/28370307
http://dx.doi.org/10.1002/hup.2576

Ejemplares similares